Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of subcutaneous sonelokimab in moderate to severe hidradenitis suppurativa
NL-OMON59316Phase 3Active, not recruiting
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Dec 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sonelokimab in hidradenitis suppurativa (HS), sponsored by MoonLake Immunotherapeutics. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 4 more. Started Dec 2025; status: active, not recruiting.
02
Drugs
sonelokimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON59316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59316.